Cambridge, MA, United States of America

Gurkan Guntas

This inventor holds 1 USPTO granted patent. Top assignee: Elstar Therapeutics, Inc.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gurkan Guntas. Retrieved from https://idiyas.com/inventor/gurkan-guntas-0mehtmjl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gurkan Guntas: Innovator in Antibody Molecule Development

Introduction

Gurkan Guntas is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibody molecules. His innovative work has the potential to impact various therapeutic applications.

Latest Patents

Gurkan Guntas holds a patent for "ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF." This patent showcases his expertise in creating novel antibody molecules that can be utilized in medical treatments.

Career Highlights

Guntas is currently associated with Elstar Therapeutics, Inc., where he continues to advance his research and development efforts. His work at the company focuses on innovative solutions in the biotechnology sector.

Collaborations

Guntas collaborates with notable colleagues, including Seng-Lai Tan and Brian Edward Vash. These partnerships enhance the research and development initiatives at Elstar Therapeutics, Inc.

Conclusion

Gurkan Guntas is a key figure in the biotechnology field, with a focus on antibody molecule innovation. His contributions and collaborations are paving the way for advancements in therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…